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Endomucin is an endothelial sialomucin that was re-
cently identi¢ed with the help of monoclonal antibo-
dies raised against mouse endothelial cells. Cloning of
human endomucin allowed us to generate monoclonal
antibodies against soluble recombinant forms of human
endomucin. In this study, we investigated the expression
of this novel molecule in human skin under di¡erent
conditions, using the monoclonal antibodies. In normal
human skin, endomucin was detected for the monoclo-
nal antibody L6H10 by immunoblotting, and immuno-
histologic analysis of wax-embedded sections revealed
that this glycoprotein is expressed on capillaries, ve-
nules, and lymphatic vessels. Interestingly, staining of
arterial endothelium was either weak or focal using the
monoclonal antibodies against endomucin. In situ hy-
bridization of normal human skin con¢rmed the ex-
pression pattern on the messenger RNA level obtained
above.We further analyzed the expression of endomucin
in skin biopsy specimens from patients with in£amma-
tory skin diseases, such as atopic dermatitis, psoriasis,
lichen planus, cutaneous lupus erythematosus, and T
cell lymphoma as well as with vascular skin tumors,
such as hemangioma, pyogenic granuloma, angiolipo-
ma, Kaposi’s sarcoma, and angiosarcoma.We found en-
domucin expressed on the endothelium of each tissue,
concluding that this novel molecule is a new endothe-
lial-speci¢c marker in the study of normal and diseased
human skin. Key words: cell adhesion molecules/selectins/
skin diseases. J Invest Dermatol 119:1388 ^1393, 2002
S
earching for endothelial-speci¢c antigens, our group
identi¢ed a novel membrane glycoprotein raising mono-
clonal antibodies (MoAb) against cell surface molecules
of a mouse endothelioma cell line. The full-length com-
plementary DNA for this molecule has been isolated by
immunoselection, and the sequence, tissue distribution, and bio-
chemical properties of this antigen, endomucin, have been pre-
viously described (Morgan et al, 1999). Endomucin codes for a
type I membrane protein of 248 amino acids and shows no sig-
ni¢cant homology to any known glycoprotein. As a typical mu-
cin-like glycoprotein, endomucin has a high content of serine
and threonine residues, suggesting strong O-glycosylation; the
sensitivity to O-sialoglycoprotein endopeptidase indicates that
endomucin is also a sialomucin. Analyzing the tissue distribution
of this sialomucin in the adult mouse, we detected the antigen
exclusively on endothelial cells of any tissue or organ that was
tested. We also found that endomucin is expressed on high en-
dothelial venules, supporting the idea that this new molecule
may be able to bind to leukocyte lectins in a manner similar
to glycosylation-dependent cell adhesion molecule-1 and CD34
(Samulowitz et al, 2002). Furthermore, tissues from various stages
of mouse embryo development revealed early expression of
endomucin on endothelium at embryo day 8.0 and on clustered
putative hematopoietic cells associated with the luminal surface
of the endothelium of the dorsal aorta (Brachtendorf et al, 2001).
Interestingly, endomucin was only weakly detectable as focal
staining on aortic endothelium at embryo day 15.5 and on the
adult aorta.
Recently, human endomucin has been identi¢ed (Samulowitz
et al, 2002), and there are great similarities on the DNA level and
on the protein level, especially in the intracellular region, be-
tween murine endomucin and its human homolog. A recombi-
nant fusion protein was generated in Chinese hamster ovary cells
and was used as immunogen to establish several MoAb against
human endomucin, all of which recognized a 95 kDa cell surface
antigen on human umbilical vein endothelial cells (HUVEC). In
this study, we investigated the tissue distribution of endomucin
in human skin at the messenger RNA and protein level and
further determined the expression pattern of this novel glycopro-
tein in in£ammatory skin diseases and vascular skin tumors using
immunohistochemical analysis.
MATERIALS ANDMETHODS
Skin biopsy specimens The presence of endomucin in normal human
skin was analyzed in para⁄n-embedded skin biopsy specimens from
the tongue (n¼1), scalp (n¼ 4), actinic and nonactinic skin (n¼ 4),
palmoplantar skin (n¼ 2), and oral and genital mucous membranes
(n¼ 4). In addition, skin specimens were analyzed from patients a¡ected
by in£ammatory skin diseases such as atopic dermatitis (n¼ 3), psoriasis
(n¼ 3), cutaneous lupus erythematosus (n¼ 3), lichen planus (n¼ 3), and
T cell lymphoma (n¼ 3) as well as by vascular skin tumors, such as
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hemangioma (n¼ 3), pyogenic granuloma (n¼ 3), angiolipoma (n¼ 3),
angiosarcoma (n¼ 3), and Kaposi’s sarcoma (n¼ 3). A total of 45 skin
biopsy specimens were obtained for histologic diagnosis, and the
remaining tissue samples were processed for immunohistochemical
analysis. Skin specimens were derived from the ¢les of the
Dermatopathology Unit, Department of Dermatology, University of
Mˇnster (Mˇnster, Germany).
Serologic markers MoAb against endomucin were produced as
previously described (Morgan et al, 1999; Samulowitz et al, 2002), and the
isotype was determined to be IgG2a for L6H10, L9H8, and L4B1. In the
staining of all wax-embedded specimens, endothelial speci¢city was
controlled by MoAb directed against human platelet endothelial cell
adhesion molecule-1 (PECAM-1) (mouse IgG1; Dako, Hamburg,
Germany), dilution 1 : 10, and human CD34 (mouse IgG1; Dako), dilution
1 : 800, as well as by a polyclonal serum directed against vonWillebrand
factor (Dako), dilution 1 : 1000.
Immunohistochemical analysis Five micrometer sections of wax-
embedded specimens were cut using a microtome and were mounted on
slides coated with poly L-lysine (Menzel-GlKser, Nuloch, Germany).
Dewaxed specimens were immersed in 10 mM sodium citrate bu¡er in
plastic Coplin jars and were incubated in an autoclave at 1201C for
10 min. Subsequently, the slides were allowed to cool to room tempera-
ture for 20^30 min, followed by reduction of endogenous peroxidase
activity with 0.1% hydrogen peroxide and 20 mM sodium azide in
Figure1. Expression of endomucin on vascular endothelium in normal human skin. Para⁄n sections of tongue (a^c), scalp (d^f), actinic skin (g^i),
palmar skin (k^m), and genital mucous membrane (n^p) were analyzed by immunohistochemical methods using the MoAb L6H10 against endomucin (a,d,g,
k,n) and, for control purposes, the polyclonal rabbit antibody against vonWillebrand factor (b,e,h,l,o) and no ¢rst antibody (c,f,i,m,p). Scale bar¼ 50 mm.
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phosphate-bu¡ered saline for 30 min at room temperature. Nonspeci¢c
binding was blocked with 2% bovine serum albumin, fraction V (Sigma,
Munich, Germany) in phosphate-bu¡ered saline, pH 7.4, for 30 min.Tissue
sections were incubated for 1 h with appropriate primary antibodies, either
as tissue culture supernatant or diluted in phosphate-bu¡ered saline
containing 1% bovine serum albumin (pH 7.4) followed by incubation
with a⁄nity-puri¢ed peroxidase-labeled donkey anti-rat IgG (dilution
1 : 1000; Dianova, Hamburg, Germany), donkey anti-mouse IgG (dilution
1 : 1000; Dianova), and goat anti-rabbit IgG (dilution 1 : 1000; Dianova).
After the reaction was visualized with 3-amino-9-ethylcarbazole, tissue
sections were counterstained with Mayer’s hematoxylin and were
mounted. All reactions were performed in a humidi¢ed chamber, and, for
control purposes, the ¢rst MoAb was either omitted or replaced by the
MoAb V5C7 or V7C7 against mouse endomucin (Morgan et al, 1999),
neither of which cross-reacts with the human antigen.
Immunoprecipitations and western blot analysis Normal human
skin has been homogenized in an Ultraturrax (Kinematica AG, Littau,
Switzerland) with lysis bu¡er (50 mM Tris^HCl, pH 7.4; 150 mM NaCl;
2% Triton X-100; 0.04% NaN3; 0.1 U per ml a2-macroglobulin; 1.0 mM
phenylmethylsulfonyl £uoride; 1.0 mM Benzamidin). The homogenate was
incubated for 1.5 h on ice and was then centrifuged for 20 min at 3000
r.p.m. (960 g) and for 15 min at 55,000 r.p.m. (164318 g) in a Beckmann
ultracentrifuge (rotor TLA 100.4); 3107 HUVEC were lyzed in 5 ml of
lysis bu¡er containing 1% Triton X-100 for 15 min on ice and were
centrifuged for 15 min at 14000 r.p.m. (20800 g) in a table-top centrifuge.
For immunoprecipitations, 40 ml of drained protein A-Sepharose beads
were incubated with 10 mg of a⁄nity-puri¢ed polyclonal rabbit anti-
endomucin antibody, which is directed against the C-terminal part
of endomucin, and with 1.0 ml of either HUVEC or skin lysate.
The immunoprecipitations were performed overnight at 41C. After
precipitation, the lysates were removed and the beads were washed three
times with washing bu¡er (25 mM Tris^HCl, pH 8.4; 250 mM NaCl;
0.05% Triton X-100; 0.04% NaN3). The immunoprecipitations were
electrophoresed, transferred to nitrocellulose ¢lters, and probed with the
MoAb L6H10 against human endomucin. For negative control purposes, a
mouse endomucin MoAb (V7C7.1) was applied. As secondary antibody, a
peroxidase-conjugated donkey anti-rat IgG (Dianova) was applied in a
dilution of 1 : 5000. Immunoreactive proteins were visualized by
enhanced chemoluminescence (ECL kit; Amersham Life Science,
Braunschweig, Germany).
In situ hybridization
Preparation of digoxigenin-labeled messenger RNA probes After linearizing of
the hEM:pcDNA3 vector (see Samulowitz et al, 2002) with appropriate re-
striction enzymes (KpnI, EcoRI), digoxigenin-labeled RNA probes were
synthesized by in vitro transcription (Boehringer Mannheim, Mannheim,
Germany). The size of the digoxigenin-labeled RNA probes was checked
on a formaldehyde gel. After ethanol precipitation, the riboprobe was re-
suspended at 10 mg per ml in a bu¡er (pH 7.5) consisting of 10 mM Tris^HCl
and 1 mM ethylenediamine tetraacetic acid.
Hybridization procedure Paraformaldehyde-¢xed, 7 mm cryostat sections
were incubated in 20 ml of hybridization solution consisting of 50%
formamide, 5% blocking reagent (Boehringer Mannheim), 5  sodium
citrate/chloride bu¡er, 0.1% N-laurylsarcosine, 0.02% sodium dodecyl sul-
fate, 100 mM Tris^HCl (pH 7.4), and 5 mM ethylenediamine tetraacetic acid,
along with the heat-denatured probe (¢nal concentration, 0.5 mg per ml).
Hybridization was carried out overnight at 401C in a humidi¢ed chamber
as previously described (Kuhn et al, 1998). After hybridization, nonhybri-
dized probes were removed by several washing procedures with 2  so-
dium citrate/chloride bu¡er and 0.1% sodium dodecyl sulfate at 501C.
Slides were then incubated with a 1 : 1000 dilution of an alkaline-phospha-
tase-labeled anti-digoxigenin antibody (Boehringer Mannheim) overnight
at 41C. Staining of the tissue sections was performed using 5-bromo-4-
chloro-3-indolyl phosphate toluidine and nitroblue tetrazolium salt as sub-
strates (Boehringer Mannheim).
RESULTS
Expression pattern of endomucin in normal human
skin To determine the expression pattern of endomucin in
normal human skin, we stained sections of wax-embedded
specimens of various tissues from tongue, scalp, palmoplantar
skin, actinic and nonactinic skin, and oral and genital mucous
membranes with the MoAb L6H10, L9H8, and L4B1. An
identical pattern of staining was observed, with all three MoAb
showing positive staining speci¢c for endothelial cells. The best
signals were obtained with the MoAb L6H10, and the results
shown in Fig 1 were all performed with this antibody. Positive
staining for endomucin was found in all tissue types examined,
and its expression was speci¢c for the vascular endothelium,
such as capillaries and venules, as well as lymphatic vessels. As
previously reported for di¡erent human tissues, such as kidney,
ileum, and suprarenal gland, staining of arterial endothelium
was patchy and focal and more di⁄cult to detect than on
venules and capillaries (Samulowitz et al, 2002). Endothelial
speci¢city was controlled by staining with antibodies directed
against von Willebrand factor, as documented in Fig 1, and
against PECAM-1 and CD34 (data not shown). In addition, for
control purposes, the ¢rst antibody was either omitted or
replaced by an irrelevant isotype-matched reagent, yielding
negative results (Fig 1). Furthermore, expression of endomucin
at the messenger RNA level was studied in specimens of normal
human skin by in situ hybridization. As shown in Fig 2,
endothelial cells in the dermis showed a strong and speci¢c
(blue) signal for endomucin in contrast to negative control.
Detection of endomucin in human skin by immuno-
precipitation and western blot analysis To support the
immunohistochemical result that endomucin is expressed in
human skin, we prepared a lysate of normal human skin and
analyzed the expression of endomucin using immuno-
precipitation and western blot analysis. As shown in Fig 3, after
immunoprecipitation with a polyclonal antibody, endomucin was
recognized by western blotting with the MoAb L6H10 in human
skin as well as in HUVEC, which were used as positive controls.
Figure 2. Expression of endomucin in specimens of normal human
skin by in situ hybridization. A speci¢c endothelial signal for endomu-
cin messenger RNAwas detected by in situ hybridization in the dermis of
normal human skin using an anti-sense probe (a) in contrast to negative
control using a sense probe (b). Scale bar¼ 50 mm.
Figure 3. Western blot analysis of endomucin in human skin. Endo-
mucin was immunoprecipitated with a polyclonal antibody against endo-
mucin from human umbilical vein endothelial cell lysates (lanes a and c) and
from lysates from normal human skin (lanes b and d). Using the MoAb
L6H10 for western blot analysis, a speci¢c signal for endomucin was de-
tected (lanes a and b), with a molecular mass of about 95 kDa. The mouse
MoAbV7C7.1was used as a negative control, and a speci¢c signal was de-
tected in neither human umbilical vein endothelial cells (lane c) nor human
skin (lane d). Molecular mass markers (in kDa) are indicated on the left.
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The mouse MoAbV7C7.1was used as a negative control and did
not detect any speci¢c signal in either HUVEC or human skin.
These data are in accordance with the immunohistochemical
results demonstrating that endomucin is constitutively expressed
in normal human skin.
Tissue distribution of endomucin in skin lesions of
in£ammatory diseases The expression of endomucin was
screened in lesional skin biopsy specimens from patients with
di¡erent in£ammatory skin diseases, such as atopic dermatitis,
psoriasis, cutaneous lupus erythematosus, lichen planus, and T
cell lymphoma. For obvious reasons, the availability of
su⁄ciently large samples of diseased human skin is limited, and
we thus used immunohistochemical methods. Endothelial-
speci¢c staining for endomucin was found in all skin specimens
using the anti-endomucin MoAb L6H10, and PECAM-1 and
CD34 (data not shown) as well as the polyclonal antibody
against von Willebrand factor (Fig 4) were used as controls.
When the ¢rst antibody was either omitted or replaced by an
irrelevant isotype-matched reagent, no staining was found.
Compared with normal human skin, there was no di¡erence in
the expression pattern of endothelial cells with respect to the
Figure 4. Expression pattern of endomucin in skin lesions from patients with di¡erent in£ammatory diseases. Para⁄n sections of atopic derma-
titis (a^c), psoriasis (d^f), cutaneous lupus erythematosus (g^i), lichen planus (k^m), and T cell lymphoma (n^p) were analyzed by immunohistochemical
methods using the MoAb L6H10 against endomucin (a,d,g,k,n) and, for control purposes, the polyclonal rabbit antibody against von Willebrand factor
(b,e,h,l,o) and no ¢rst antibody (c,f,i,m,p). Scale bar¼ 50 mm.
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vascular endothelium of venules, capillaries, and lymphatic vessels.
Staining for arterial endothelium showed the same kind of
weakness in all tissues examined as seen in normal human skin.
Tissue distribution of endomucin in skin lesions of vascular
tumors Skin biopsy specimens from patients with benign or
malignant vascular skin tumors were stained with the MoAb
L6H10 against endomucin to investigate whether this novel
molecule is di¡erentially regulated in conditions such as
hemangioma, pyogenic granuloma, Kaposi’s sarcoma, angio-
lipoma, and angiosarcoma (Fig 5). An endothelial-speci¢c
staining pattern was found in capillaries, venules, and lymphatic
vessels in all tissues, with no di¡erence regarding the di¡erent
vascular tumors; immunohistochemical staining of arterioles
and arteries was either weak or focal using the MoAb against
endomucin. Undi¡erentiated vessels in pyogenic granuloma
were stained more weakly compared with highly di¡eren-
tiated vessels, and, in angiosarcoma, pre-existing vessels
showed more intense staining than did tenuous vascular slits
of the tumor. For control purposes, antibodies against von
Willebrand factor (Fig 5), PECAM-1, and CD34 (data
not shown) were used; as a negative control, the ¢rst
Figure 5. Expression pattern of endomucin in skin lesions from patients with benign and malignant vascular tumors. Para⁄n sections of he-
mangioma (a^c), pyogenic granuloma (d^f), Kaposi’s sarcoma (g^i), angiolipoma (k^m), and angiosarcoma (n^p) were analyzed by immunohistochemical
methods using the MoAb L6H10 against endomucin (a,d,g,k,n) and, for control purposes, the polyclonal rabbit antibody against von Willebrand factor
(b,e,h,l,o) and no ¢rst antibody (c,f,i,m,p). Scale bar¼ 50 mm.
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antibody was either omitted or replaced by an irrelevant isotype-
matched reagent.
DISCUSSION
Using a panel of novel MoAb and polyclonal antibodies against
the human ortholog of endomucin, we previously demonstrated
the largely endothelial nature of this antigen (Samulowitz et al,
2002). To determine the tissue distribution of this novel molecule
in human skin under di¡erent conditions, in this study we
stained sections of wax-embedded specimens of various human
skin tissues with di¡erent MoAb against endomucin. Immuno-
histochemical analysis revealed no di¡erence with these antibo-
dies, showing that endomucin is expressed in all examined tissue
samples from normal human skin, including tongue, scalp, acti-
nic and nonactinic skin, palmoplantar skin, and mucous mem-
branes on venous endothelium, capillaries, and lymphatic
vessels. In these tissues, expression on the endothelium of arter-
ioles was either focal or showed weak staining for endomucin
compared with control endothelial-speci¢c antibodies. Further-
more, we prepared a lysate of normal human skin and analyzed
the expression of endomucin using immunoprecipitation and im-
munoblotting. As detected by the MoAb L6H10, endomucin cor-
responded to the 95 kDa protein expressed on HUVEC, which
was used as a positive control. The expression of endomucin
at the messenger RNA level was also studied in specimens of
normal human skin by in situ hybridization, showing a strong
signal for endomucin on endothelial cells.
The role of endomucin during in£ammation and tumor
angiogenesis is unknown, and we therefore investigated the
expression pattern of endomucin in di¡erent skin diseases. Anti-
gen expression was unchanged in all of the analyzed in£amma-
tory diseases, including atopic dermatitis, lichen planus, psoriasis,
cutaneous lupus erythematosus, and T cell lymphoma, as well
as in all of the vascular skin tumors, including hemangioma,
pyogenic granuloma, angiolipoma, Kaposi’s sarcoma, and angio-
sarcoma.The expression of endomucin was speci¢c for the vascu-
lar endothelium of venules, capillaries, and lymphatic vessels, and
focal or weak staining was detected on arterioles and arteries,
concluding that the tissue distribution of endomucin suggests
that it serves a speci¢c, yet unknown, function important in
endothelial cells. In a recent study, it was reported that the expres-
sion of endomucin can be upregulated by growth stimulation and
by tumor-conditioned medium as well as by speci¢c angiogenic
factors, suggesting that endomucin might function as a speci¢c
marker of proliferating endothelial cells and might play a part in
tumor angiogenesis (Liu et al, 2001). At this point, however, our
data do not support the idea that the regulation of endomucin
expression is causally involved in the formation of various skin
tumors examined in this study. Instead, we showed that signi¢-
cant changes in endomucin expression can be excluded in in£am-
mation and tumor angiogenesis, although subtle di¡erences in
the expression level of endomucin cannot be seen by immuno-
histochemical analysis.
It is still unclear at the present time whether endomucin has
adhesive or anti-adhesive activity or whether it might be involved
in signal transduction. As a typical sialomucin, endomucin be-
longs to a heterogeneous class of highly O-glycosylated, sialic
acid-rich glycoproteins that enables them to be highly accessible
on the cell surface and therefore allows some of them either to
support or prevent cell adhesion. Most proadhesive sialomucins
serve as ligands for the selectins, which are cell adhesion mole-
cules that recognize carbohydrate structures and mediate the in-
itiation of the cell contact between leukocytes and endothelial
cells (Bevilacqua and Nelson, 1993; McEver, 1994; Vestweber,
1997). Indeed, in a recent study (Samulowitz et al, 2002), we de-
monstrated strong expression of endomucin on high endothelial
venules in mouse and human lymphoid organs, suggesting that
endomucin could serve as a ligand for L-selectin. This hypothesis
was strongly supported by the detection of endomucin as a car-
rier of the MECA-79 epitope, a denominator of peripheral node
addressins, and by the fact that staining of endomucin was re-
stricted to the luminal domain of high endothelial venules. In
contrast, staining with the MECA-79 was more widely distribu-
ted, extending into the more basal areas (Samulowitz et al, 2002).
Furthermore, the distribution of endomucin on venules of all ex-
amined tissues would also provide endomucin as a potential car-
rier of the MECA-79 epitope at sites of chronic in£ammation,
where this epitope is inducible; however, depending on the type
of cell that expresses endomucin and on the type of glycosylation,
endomucin may serve di¡erent functions. Recently, it has been
suggested that endomucin has anti-adhesive activity (Kinoshita
et al, 2001; Ueno et al, 2001).
In conclusion, our results show that endomucin is expressed on
the endothelium along the vascular tree, with the exception of
the patchy staining on most arterial vessels, and that it serves as
a new endothelial-speci¢c marker in the study of normal and dis-
eased human skin. The physiologic function of this novel mole-
cule in in£ammation and tumor angiogenesis, however, must be
elucidated in future experiments, and whether endomucin can
potentially be targeted in the diagnosis or treatment of human
diseases needs to be analyzed.
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